Genmab — Oktober 2014
-
-
PCYC stiger godt i premarkedet på gode Imbruvica salgstal fra J&J
-
Glæder mig til at om et års tid når vi også kan se frem til J&J regnskabspræsentationerne og finde vores kvartalsvise Daratumumab royalty
-
Men anonyme får købt lidt nu. nordea har været sælgere i de sidste 14 dage
-
Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”
Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.
(modular protein therapeutic) platform targeting human CD37.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind